MX2019000735A - Antagonistas opioides kappa de tetrahidroisoquinolina. - Google Patents

Antagonistas opioides kappa de tetrahidroisoquinolina.

Info

Publication number
MX2019000735A
MX2019000735A MX2019000735A MX2019000735A MX2019000735A MX 2019000735 A MX2019000735 A MX 2019000735A MX 2019000735 A MX2019000735 A MX 2019000735A MX 2019000735 A MX2019000735 A MX 2019000735A MX 2019000735 A MX2019000735 A MX 2019000735A
Authority
MX
Mexico
Prior art keywords
kappa opioid
tetrahydroisoquinoline
opioid antagonists
opioid receptor
eating disorders
Prior art date
Application number
MX2019000735A
Other languages
English (en)
Inventor
Ivy Carroll Frank
M Kormos Chad
W Ondachi Pauline
A Navarro Hernan
B Thomas James
S Wayne Mascarella
P Runyon Scott
Original Assignee
Res Triangle Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Triangle Inst filed Critical Res Triangle Inst
Publication of MX2019000735A publication Critical patent/MX2019000735A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se describen antagonistas del receptor opioide potentes y su uso como farmacoterapias para tratar depresión, ansiedad, esquizofrenia, trastornos de alimentación, y adicción a la cocaína, metanfetamina, nicotina, alcohol, apiatos, De manera más específica, la descripción proporciona compuesto antagonistas del receptor opiode kappa potentes y selectivos, composiciones farmacéuticas de aquellos compuestos y usos de aquellos compuestos para aminorar o tratar adicciones, trastornos de alimentación, etcétera.
MX2019000735A 2016-09-16 2017-09-15 Antagonistas opioides kappa de tetrahidroisoquinolina. MX2019000735A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662395750P 2016-09-16 2016-09-16
PCT/US2017/051707 WO2018053222A1 (en) 2016-09-16 2017-09-15 Tetrahydroisoquinoline kappa opioid antagonists

Publications (1)

Publication Number Publication Date
MX2019000735A true MX2019000735A (es) 2019-12-02

Family

ID=59969256

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019000735A MX2019000735A (es) 2016-09-16 2017-09-15 Antagonistas opioides kappa de tetrahidroisoquinolina.

Country Status (9)

Country Link
US (1) US11292783B2 (es)
EP (1) EP3512832B1 (es)
JP (1) JP7048572B6 (es)
CN (1) CN109790125B (es)
AU (1) AU2017325870B2 (es)
CA (1) CA3032046A1 (es)
ES (1) ES2875329T3 (es)
MX (1) MX2019000735A (es)
WO (1) WO2018053222A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11266627B1 (en) 2021-05-04 2022-03-08 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
US20220370409A1 (en) 2021-05-04 2022-11-24 Janssen Pharmaceuticals, Inc. Compositions And Methods For The Treatment Of Depression
TW202345796A (zh) 2022-03-07 2023-12-01 美商健生醫藥公司 阿替卡普蘭（ａｔｉｃａｐｒａｎｔ）之形式

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3704322A (en) * 1969-09-24 1972-11-28 Malesci S A S Inst Farmacobiol N-alkyl-n'-(1-naphthoyl) ethylene diamines
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US5571792A (en) 1994-06-30 1996-11-05 Warner-Lambert Company Histidine and homohistidine derivatives as inhibitors of protein farnesyltransferase
EP0841922B1 (en) * 1995-05-30 2002-02-20 Gliatech, Inc. 1h-4(5)-substituted imidazole derivatives
US5932590A (en) 1996-12-05 1999-08-03 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
EP1468999A1 (en) 2003-03-20 2004-10-20 MyoContract Ltd. Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators
US20040204453A1 (en) 2003-04-14 2004-10-14 Pfizer Inc 4-Phenyl-piperidine compounds and their use as modulators of opioid receptors
JP2007529523A (ja) 2004-03-15 2007-10-25 イーライ リリー アンド カンパニー 肥満症を治療するためのオピオイド受容体拮抗物質としての４−（５−アミノメチル）−インドール−１−イルメチル）−ベンズアミド誘導体および関連化合物
EP1966169A2 (en) 2005-12-29 2008-09-10 Immupharma France SA Compositions and methods for the inhibition of phospholipase a2
US7777030B2 (en) * 2005-12-29 2010-08-17 Centre National de la Recherge Scientifique (CNRS) Compositions and methods for the treatment and prevention of disease
JP5464395B2 (ja) 2008-02-01 2014-04-09 大陽日酸株式会社 重水素化された芳香環又は複素環を有する化合物の製造方法
US8048895B2 (en) 2008-04-18 2011-11-01 Research Triangle Institute Kappa opioid receptor ligands
WO2009154754A2 (en) 2008-06-17 2009-12-23 Concert Pharmaceuticals, Inc. Synthesis of deuterated morpholine derivatives
EP2334621A1 (en) 2008-09-16 2011-06-22 Concert Pharmaceuticals, Inc. Deuterated 2-amino-3-hydroxypropanoic acid derivatives
AU2010346633B2 (en) 2010-02-24 2015-12-03 Research Triangle Institute Arylpiperazine opioid receptor antagonists
US20140080810A1 (en) 2010-11-15 2014-03-20 Exelixis, Inc. Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture
EP2714624B1 (en) 2011-05-23 2017-12-27 Sanofi Process for the preparation of deuterated compounds containing n-alkyl groups
JP5612628B2 (ja) 2012-04-20 2014-10-22 日立アプライアンス株式会社 密閉型圧縮機
EP2897615A4 (en) 2012-09-18 2016-04-27 Auspex Pharmaceuticals Inc PHARMACOKINETIC FORMULATIONS OF DEUTERATED BENZOCHINOL INHIBITORS OF THE VESICLE MONOAMINE TRANSPORTER 2
EP2935251A1 (en) 2012-12-20 2015-10-28 Concert Pharmaceuticals Inc. Deuterated alk inhibitors
CA2909270A1 (en) 2013-04-12 2014-10-16 Achillion Pharmaceuticals, Inc. Highly active nucleoside derivative for the treatment of hcv
SG11201602962PA (en) 2013-10-17 2016-05-30 Vertex Pharma Co-crystals of (s)-n-methyl-8-(1-((2'-methyl-[4,5'-bipyrimidin]-6-yl)amino)propan-2-yl)quinoline-4-carboxamide and deuterated derivatives thereof as dna-pk inhibitors
WO2015109080A1 (en) 2014-01-15 2015-07-23 Research Triangle Institute Kappa-opioid receptor selective opioid receptor antagonists

Also Published As

Publication number Publication date
EP3512832B1 (en) 2021-05-19
WO2018053222A8 (en) 2018-04-26
ES2875329T3 (es) 2021-11-10
JP2019531260A (ja) 2019-10-31
AU2017325870B2 (en) 2021-07-22
EP3512832A1 (en) 2019-07-24
US20190263781A1 (en) 2019-08-29
AU2017325870A1 (en) 2019-02-07
CN109790125A (zh) 2019-05-21
CN109790125B (zh) 2022-07-05
JP7048572B6 (ja) 2023-12-20
WO2018053222A1 (en) 2018-03-22
CA3032046A1 (en) 2018-03-22
US11292783B2 (en) 2022-04-05
JP7048572B2 (ja) 2022-04-05

Similar Documents

Publication Publication Date Title
PH12015501832A1 (en) Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders
IL263947A (en) Compositions and methods for the preparation of benzylisoquinoline alkaloids, morphinan alkaloids, tibean and their derivatives
MX342161B (es) Compuestos antagonistas selectivos de receptor nk-3 novedosos, composicion farmaceutica y metodos para utilizarse en trastornos transmitidos por receptores nk-3.
MX2016011632A (es) Derivados de azaspiro como antagonistas de trpm8.
ATE533762T1 (de) Chinolin- oder isochinolinsubstituierte p2x7- antagonisten
PH12015502658A1 (en) 3,4-dihydroisoquinolin-2 (1h)-yl compounds
SA518400333B1 (ar) شكل متعدد الأشكال من n- {6-(2-هيدروكسي بروبان-2-يل) -2-[2-(مثيل سلفونيل) إثيل]-2h-إندازول-5-يل}-6-(ثلاثي فلورومثيل) بيريدين-2-كربوكساميد
BR112015024907A2 (pt) n-acil-(3-substituido)-(8-substituido)-5,6-dihidro-[1,2,4]triazol[4,3a]pirazinas como antagonistas receptores seletivos de nk-3, composição farmacêutica, métodos para uso em desordens mediadas por receptores de nk-3
MX2019000735A (es) Antagonistas opioides kappa de tetrahidroisoquinolina.
WO2012003418A3 (en) Functionally selective ligands of dopamine d2 receptors
MX2013008431A (es) Antagonista del receptor de mineralocorticoides.
MX2017013219A (es) Sales de maleato de un inhibidor de b-raf quinasa, formas cristalinas, metodos de preparacion y por consiguiente sus usos.
WO2015100092A3 (en) 7-beta analogs of orvinols
TN2016000263A1 (en) 1,2-substituted cyclopentanes as orexin receptor antagonists
MX2016005759A (es) Derivados de piridina sustituidos, utiles como inhibidores de glucogeno sintasa cinasa 3 (gsk-3).
MX2017012720A (es) Antagonistas duales de receptores de neurocinina-1 (nk-1) / neurocinina-3 (nk-3) para el tratamiento de enfermedades dependientes de hormonas sexuales.
WO2016100349A3 (en) Bicyclic azaheterocyclic compounds as nr2b nmda receptor antagonists
TW201613884A (en) Selective NR2B antagonists
MX370612B (es) Benzazepinas fusionadas para el tratamiento de la tartamudez.
EA201791881A1 (ru) Производные 2-аминопиридина в качестве антагонистов рецептора аденозина aи лигандов рецепторов мелатонина mt
EA201692227A1 (ru) Производные сложных аминоэфиров
NZ741384A (en) Dopamine d3 receptor antagonists having a morpholine moiety
BR112017020384A2 (pt) antagonistas do receptor do tipo toll 4 e uso em doenças hepáticas autoimunes
BR112015004254A2 (pt) antagonistas dos receptores de quimiocina
MX2018004256A (es) Antagonistas de receptor de n-metil-d-aspartato subtipo 2b (nr2b) selectivos.